Original from: 360dx

In preliminary results reported on Wednesday after the close of the market, Becton Dickinson said its revenues in the fiscal fourth quarter of 2025 increased 8 percent year over year. The firm also announced the upcoming departure of its CFO and disclosed a transition plan for the position.

BD's preliminary fiscal Q4 revenues were approximately $5.89 billion, an increase of 7 percent on a currency-neutral basis and up 4 percent on an organic basis compared to total revenues of $5.44 billion in the prior-year quarter.

For fiscal 2025, BD reported its preliminary revenues rose 8 percent to $21.84 billion, an increase of 8 percent on a currency-neutral basis and up approximately 3 percent on an organic basis compared to $20.18 billion in fiscal 2024. 

BD said it expects to deliver full-year fiscal 2025 adjusted diluted EPS at or above the midpoint of its previously issued guidance, updated in August to $14.30 to $14.45.  

Tom Polen, president and CEO of BD, said in a statement that the firm continues to navigate a dynamic macroeconomic environment that impacted biosciences in academic and government research, among other areas.

Becton Dickinson announced in July that it intends to sell its biosciences and diagnostic solutions businesses to Waters for $17.50 billion, adding molecular biology and microbiology offerings to Waters' clinical portfolio.

Chris DelOrefice, who has served as Becton Dickinson's CFO since 2021, will depart in early December to pursue a new professional opportunity, BD also announced. 

The Franklin Lakes, New Jersey, company is now conducting a search for a permanent successor, and Vitor Roque, the current senior VP of finance, business units, and corporate financial planning, will serve as interim CFO.

In Thursday afternoon trading on the NYSE, shares of BD were down approximately 2 percent to $183.56. 

Source: Becton Dickinson Preliminary Fiscal Q4 Revenues up 8 Percent